On May 17, 2019 Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, reported that it will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine during the annual congress of the European Hematology Association (EHA) (Free EHA Whitepaper) taking place from 13 – 16 June in Amsterdam (Press release, MediGene, MAY 17, 2019, View Source [SID1234536462]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Medigene will present a poster on June 15 from 17:30-19:00 entitled "Interim Analysis of a WT-1 and PRAME ` Fast-DC´ vaccine shows safety as active immunotherapy for the prevention of AML relapse".

For the full abstract of the poster, please follow this link:
View Source
or View Source